Abstract
In an uncontrolled open trial, 317 outpatients suffering from soft-tissue rheumatisms (ie, 148 patients with painful shoulder, 92 with tendinitis, 42 with epicondylitis, and 35 with minor traumas) received 450 mg/day of proglumetacin, a prodrug of indomethacin. After 7 days of treatment, a highly significant reduction in pain and an improvement of function were observed in all groups of patients ( P < 0.001). The incidence of side effects (13.8%), mainly gastrointestinal (10.1%), was low, especially compared with that classically described for indomethacin. More than 50% of the patients who developed side effects were able to continue proglumetacin treatment, and only one fifth of them (ie, 2.8% of all patients in the study) had to discontinue the treatment. For the short-term treatment of soft-tissue rheumatisms, proglumetacin appears to be a safe nonsteroidal anti-inflammatory compound that is associated with a reduction in pain and an improvement in function in treated patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
